Sanofi-Aventis Considers Taxotere Name Change To Avoid Misuse In Japan
This article was originally published in PharmAsia News
Sanofi-Aventis is considering a name change for cancer drug Taxotere (docetaxel) in Japan, according to officials at Japan's Ministry of Health, Labor and Welfare
You may also be interested in...
The sellers of the anti-aging “cure-all” reached an agreement with the FTC in February that prohibits them from making false and unsubstantiated health claims and requires them to pay $660,000 in total to the Commission. Refund checks now are being issued to more than 1,300 defrauded consumers.
Exits from Pfizer and Gilead as executives move to Oligomerix Inc. and Pandion Therapeutics, respectively, while chief medical officers are appointed at Exicure and Larimar Therapeutics Inc.
Santhera needs more time to address concerns regarding its current EU application for idebenone in the DMD setting but the Swiss biotech is keeping its sights on a broader indication.